Results 121 to 130 of about 54,799 (219)

Facts and Misfacts on D‐Dimer Testing. Consensus Guidance From the Italian Society on Thrombosis and Hemostasis (SISET)

open access: yesAmerican Journal of Hematology, Volume 101, Issue 1, Page 97-109, January 2026.
ABSTRACT D‐dimer defines degradation products derived from the proteolysis mediated by plasmin on cross‐linked fibrin. The evidence‐based use of D‐dimer in some conditions has been consolidated. Currently, however, there is an entrenched prescription of D‐dimer testing to screen otherwise healthy subjects that may induce prescribing physicians to start
Armando Tripodi   +11 more
wiley   +1 more source

A Comparison of a Drug Coated Balloon With Drug Eluting Stent Strategy for Treating Coronary Bifurcation Lesions

open access: yesCatheterization and Cardiovascular Interventions, Volume 107, Issue 1, Page 3-14, January 1, 2026.
ABSTRACT Background The treatment of coronary bifurcation lesions (CBL) remains complex and associated with a higher rate of long‐term adverse cardiovascular events due to anatomical and procedural complexity. Aims We compared procedural outcomes between a drug coated balloon (DCB) only approach and a 2nd generation drug eluting stent (DES) for ...
Natasha Corballis   +20 more
wiley   +1 more source

Missed Kawasaki Disease With Coronary Aneurysms and Familial Hyperlipidemia: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
ABSTRACT Atypical Kawasaki disease may be missed, leading to severe coronary complications. Physians should suspect Kawasaki disease in infants with prolonged fever and elevated inflammatory markers, even without the classic features, providing long‐term cardiac and lipid monitoring.
Roddy Gergeus   +4 more
wiley   +1 more source

Association of Obstructive Sleep Apnea With Cardiovascular Outcomes in Patients With Acute Coronary Syndrome. [PDF]

open access: yes, 2019
Background The prognostic significance of obstructive sleep apnea ( OSA ) in patients with acute coronary syndrome ( ACS ) in the contemporary era is unclear.
Fan, Jingyao   +5 more
core   +1 more source

Incremental Value of Non‐Gated Chest CT Coronary Artery Calcium Score in Predicting Major Adverse Cardiovascular Events by GRACE Score After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome

open access: yesClinical Cardiology, Volume 49, Issue 1, January 2026.
This study confirms that the combined GRACE score and coronary artery calcium score significantly improves the predictive efficacy of the risk of major adverse cardiovascular events (MACE) after percutaneous coronary intervention (PCI) in patients with acute coronary syndrome (ACS), and the predictive value is even better when combined with clinical ...
Zhaoyuan Xing   +8 more
wiley   +1 more source

Vital systems, Grand body systems: Cardiovascular systems

open access: yesنشریه پرستاری ایران, 1995
Unstable angina has progressive process and even in rest time, it happens frequently. It is a serious situation and 15-20 percent of patients are dying in duration of one year. Treatment: patients often hospitalized because observation of their reactions
Farahaninia, M
doaj  

Rationale and Design of the PASSIVATE‐CAP Trial: The Preventive Intervention Value of Drug‐Coated Balloons in Vulnerable Coronary Atherosclerotic Plaques

open access: yesClinical Cardiology, Volume 49, Issue 1, January 2026.
PASSIVATE‐CAP Research Overview and Flowchart. ABSTRACT Background Patients with acute coronary syndrome (ACS) face a significantly increased risk of cardiovascular events due to vulnerable plaques. However, no clear evidence supports performing preventive percutaneous coronary intervention (PCI) for non‐flow‐limiting vulnerable plaques.
Zhongxiu Chen   +11 more
wiley   +1 more source

Impact of Antihypertensive Treatment on Outcomes of Adjuvant Bevacizumab for Ovarian Cancer (IATRO), Results from a Nationwide Emulated Clinical Trial

open access: yesClinical Pharmacology &Therapeutics, Volume 119, Issue 1, Page 198-207, January 2026.
Antiangiogenic therapy with bevacizumab improves outcomes in ovarian cancer but induces hypertension, leading to major adverse cardiovascular events (MACE). While calcium channel blockers (CCBs) and angiotensin‐converting enzyme inhibitors (ACEi) are recommended for managing bevacizumab‐associated hypertension, their impacts on cancer progression and ...
Floriane Jochum   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy